Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01924169 · ClinicalTrials.gov registry record · Phase 2
Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL)
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT01924169: Clinical Trial Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT01924169 is a Phase 2 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01924169, a Phase 2 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if lenalidomide can increase the level of immunoglobulins (parts of the blood that may help to improve the immune system's function) and/or will improve the protective effect of the flu and pneumonia vaccines in patients with CLL.
Interventions
- DRUG Lenalidomide
- BIOLOGICAL Influenza Vaccine
- BIOLOGICAL Pneumovax Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2014-11-24 |
| Est. Completion | 2017-02-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01924169
The ClinicalTrials.gov registry entry for NCT01924169 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Lenalidomide is the first listed.
NCT01924169 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01924169 about?
NCT01924169 is a clinical study titled "Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL)". The goal of this clinical research study is to learn if lenalidomide can increase the level of immunoglobulins (parts of the blood that may help to improve the immune system's function) and/or will improve the protective effect of the flu and pneumonia vaccines in patients with CLL.
What is the current status of trial NCT01924169?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2014-11-24. Estimated completion is 2017-02-21.
What interventions are being tested in trial NCT01924169?
The interventions under investigation include: Lenalidomide (DRUG), Influenza Vaccine (BIOLOGICAL), Pneumovax Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01924169?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.